

CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP

SEPTEMBER 9, 2026

VIRTUAL MEETING RECAP

There were 38 members and guests at this virtual meeting. We also welcomed 1 new member

Guest Speaker: Adaptive Biotechnologies

Dr. Christina Spencer, Senior Medical Science Liaison Midwest

Sammi Lotti, Fernando Para Chong

Topic: Dr. Christina spoke about Adaptive Biotechnologies MRD test, ClonoSEQ

Below is the link to the video of the meeting and her presentation.

https://us02web.zoom.us/rec/share/IGciJInYyny_3DnebBV2QSMzYCqm29yyiN3UAvRuA1AWyBdpErOvRCFnLzmjyQsz.3l6LXnQi8zkBmas?startTime=1788993575000

Passcode: R=92ijYv

Myeloma News:

- The International Myeloma Foundation Mourns the Passing of Former IMF Board Member Dr. Robert A. Kyle — The Father of Multiple Myeloma

- “Standing on the Shoulders of Giants” Dr. Robert Kyle and Dr. Mohamad Mohty
- <https://pmc.ncbi.nlm.nih.gov/articles/PMC10063761/>
 - Dr. Mohty interviews Dr. Kyle
- “Memoir” – A Physician’s Journey: The Memoir of Robert A. Kyle, MD
- September Is Blood Cancer Awareness Month
- FDA Approves Zenbexus (Iberdomide) Combination for Patients With Multiple Myeloma After Prior Treatment
 - U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
- Ententamig Improves Responses and Progression-Free Survival in Relapsed Multiple Myeloma
- Bristol Myers Squibb Reports Positive Results for CAR T-Cell Therapy in Heavily Pretreated Multiple Myeloma
- Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
- AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Ententamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

Upcoming Events:

International Myeloma Foundation

<https://www.myeloma.org/>

- Register for a FREE IMF Patient and Family Seminar in Short Hills, NJ
 - October 2-3 2026
 - <https://www.myeloma.org/events/short-hills-nj-patient-family-seminar-2026>
- Special Interest Support Groups
 - **Multiple Myeloma Care Partner Support Group (virtual)**
 - **September 10 @7:00 pm EDT**
 - **Las Voces de Mieloma**
 - **@ 1:00 pm EDT**
 - **Living Solo and Strong with Myeloma**
 - **October 6 @ 6:00 pm EDT**
 - **Living Well with High Risk Multiple Myeloma**
 - **Meets 3rd Thursday of each month, alternating daytime/evening hours. Odd months, 12:00 pm ET, even months 7:00 pm EDT. Next meeting September 17 @ 12:00 pm EDT**
 - **MGUS 4 US**
 - **Please email Emily Gordon at erg2172@cumc.columbia.edu if you have questions or for meeting information**
 - **Smolder Bolder**
 - **Sept 14 @ 7:30-9:30 pm EDT**
 - **Strength Through Inspiration: A Virtual Support Group for Multiple Myeloma Patients & Caregivers who have Young Children (every other month)**
 - **September 8 @ 8:00-9:00 pm EDT**

- **The Veterans with Myeloma Special Interest Group (Virtual)**
 - **Meets the 4th Wednesday of the month. For more information or to sign up for group emails visit**
 - <https://www.myeloma.org/support-group/veterans-myeloma-special-interest-group>
 - **September 23 @ 5:00 pm EDT**
- **Myeloma in the Middle**
 - **September 15 @ 7:30 pm EDT**
- **Other Events**
 - **Facebook Live Q&A**
 - **Dr. Douglas Sborov**
 - **Tue, 09/29/2026 - 7:00pm EDT**

Multiple Myeloma Research Foundation

<https://themmrf.org/>

- **2026 MMRF NYC Walk**
 - **This year to Honor Myeloma Advocate and Patient Terry Glassman (Long Island MM Support Group Leader)**
 - **October 10 @ 8:00am**
 - **Pier 17, NYC**
- **Beyond the Headlines: What New Research at IMS Means for Patients**
 - **September 30 @ 5:00 pm EDT**

- Patient Summit in Partnership with UCSF Health
 - October 24 @ 11:00 am EDT
- Patient Summit in Partnership with University of Miami
 - November 5 @4:00pm EDT

Blood Cancer United (formerly LLS)

<https://bloodcancerunited.org/>

Weekly Online Chat:

- **Veterans Living with Blood Cancer**
 - **Every Tuesday Evening @ 8:00-10:00pm EDT**
- **Online Chat for Caregivers:**
 - **Every Thursday Evening @ 8:00-10:00 pm EDT**
- **Online Chat Living with Myeloma:**
 - **Every Monday Evening @ 8:00-10:00 pm EDT**
- **Online Chat for Patients and Caregivers - Banding Together: Feeling Good Fridays**
 - **Every Friday @ 1:00-3:00 pm EDT**

Triage Cancer

<https://triagecancer.org/>

- Events
 - **Webinars**
 - **Open Enrollment: Reviewing, Reevaluating, Renewing**
 - **September 22 @ 2:00pm EDT**

- **Understanding Changes to Medicaid & the Marketplace: What Patients and Caregivers Need to Know**
 - **October 1 @ 7:00pm EDT**
- **Make the Most of Medicare Open Enrollment**
 - **October 13 @ 2:00pm EDT**

SUPPORT GROUP NEWS:

- 14th Annual Miracles for Myeloma 5K Run/Walk Hybrid Edition
 - The Race is on!!! This Saturday, September 19th at Oak Ridge Park, Clark NJ. Check in starts at 7:30am and Race begins at 9:30am, runners starting off first.
 - It is not too late to register! Or Donate! Or purchase a Remembrance Path Placard!
 - The amount raised for the Race so far is close to \$60K. Of that amount, the Central NJ MM Support Group has 7 Teams and has raised over \$26K!!! Thank you so much for your donations and support.
 - <https://fundraise.myeloma.org/event/2026-miracles-for-myeloma-virtual-in-person-5k-run-walk-clark-nj/e772793>
- Upcoming Meeting Information
 - October 7 – Tom Whitehead, father of Emily Whitehead the first pediatric patient treated with the then experimental CAR t-cell therapy in 2012 at CHOP/Philadelphia at age 7. Emily remains cancer free today. He is also the President and Co-Founder of the Emily Whitehead Foundation

- October 14 – Last in person meeting at Steeplechase Cancer, Somerville for 2026. Meeting time 5:30-7:30 pm. More information to follow
- November 4 – Jim Gano, MM survivor, motivational speaker, and author of the book, I'm Not Done Yet.
- Dec 2 – Cindy Ness, PhD, EdD, LCSW founder of The Center for Cancer Lifestyle Management

Please email the group with any speaker suggestions or speaker topics for 2027!!

CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP
SEPTEMBER 9, 2026 VIRTUAL MEETING RECAP
INFORMATIONAL MYELOMA LINKS

International Myeloma Foundation

<https://www.myeloma.org/>

- The International Myeloma Foundation Mourns the Passing of Former IMF Board Member Dr. Robert A. Kyle — The Father of Multiple Myeloma
- September Is Blood Cancer Awareness Month
- iStopMM Headline Results and Redefining Light Chain Precursors: Author Insights Into New iStopMM Publications
- Register for a FREE IMF Patient and Family Seminar in Short Hills, NJ
 - October 2-3 2026
 - <https://www.myeloma.org/events/short-hills-nj-patient-family-seminar-2026>

Resources and Support

- Find a Support Group
- **Multiple Myeloma Care Partner Support Group (virtual)**
 - **September 10 @7:00 pm EDT**
- **Las Voces de Mieloma**
 - **@ 1:00 pm EDT**
- **Living Solo and Strong with Myeloma**
 - **October 6 @ 6:00 pm EDT**
- **Living Well with High Risk Multiple Myeloma**
 - **Meets 3rd Thursday of each month, alternating daytime/evening hours. Odd months, 12:00 pm ET, even months 7:00 pm EDT. Next meeting September 17 @ 12:00 pm EDT**
- **MGUS 4 US**
 - **Please email Emily Gordon at erg2172@cumc.columbia.edu if you have questions or for meeting information**

- **Smolder Bolder**
 - **Sept 14 @ 7:30-9:30 pm EDT**
- **Strength Through Inspiration: A Virtual Support Group for Multiple Myeloma Patients & Caregivers who have Young Children (every other month)**
 - **September 8 @ 8:00-9:00 pm EDT**
- **The Veterans with Myeloma Special Interest Group (Virtual)**
 - **Meets the 4th Wednesday of the month. For more information or to sign up for group emails visit**
 - <https://www.myeloma.org/support-group/veterans-myeloma-special-interest-group>
- **September 23 @ 5:00 pm EDT**
- **Myeloma in the Middle**
 - **September 15 @ 7:30 pm EDT**

Contact the Info Line

<https://www.myeloma.org/infoline>

Care Partner Resources

Find a Clinical Trial

Myeloma Knowledge Platform

Patient /Family Seminars

Community Workshops

Weekly Newsletter

Mind, Body, Wellness

Patient Perspective at ASH

Diversity, Equity, and Inclusion

External Resources

Drug Reimbursement and Co-Pay Assistance Resources

Financial Resources

Government Resources

Counseling and Support Resources

Housing and Travel Resources

International Support

Legal Resources

Pain Management Resources

Transplant Resources

Other Cancer Resources

News

- IMF Chairperson of the Board Dr. S. Vincent Rajkumar and IMF SAB Member Dr. Shaji Kumar Co-Author Study on 'Redefining Plasma Cell Leukemia'
 - <https://www.myeloma.org/news-events/multiple-myeloma-news/personal-view-plasma-cell-leukemia>
- August 2026 – Myeloma News from the Journals
- Phase 3 CERVINO Trial Shows Etentamig Significantly Improves Response Rate and Progression-Free Survival in Relapsed/Refractory Myeloma

- Phase 2 QUINTESSENTIAL Trial Results: GPRC5D-targeted CAR T (arilo-cell) Showed Significant Overall Response Rate in Relapsed/Refractory Myeloma

Events

- Facebook Live Q&A
 - Dr. Douglas Sborov
 - Tue, 09/29/2026 - 7:00pm EDT
- Patient and Family Seminar 2026
 - Short Hills, NJ
 - Oct 2-3
 - Beginning Oct 2 @ 12:00 pm EDT
 - Seating is limited

Blogs

- The Road to the Cure: 2026 Marks the Closest the Myeloma Community Has Come to the Finish Line
- July and August 2026: What's New in Myeloma?
- iStopMM Headline Results and Redefining Light Chain Precursors: Author Insights Into New iStopMM Publications

Videos (**New Page Design**)

- Myeloma Made Simple
- Myeloma in a Minute
- Emerging Therapies
- Symptom Management
- Facebook Live
- Living Well with Myeloma
- Myeloma University
- Community Workshop

What is Multiple Myeloma

- Newly Diagnosed
- Tests and Staging
- Treatment

Publications and Broadcasts

- IMF Publications
- IMF Broadcasts
- Healthcare Professional Resource

Resources and Support

- IMF Support Network
 - Diversity, Equity, Inclusion
 - **External Resources**
 - **Drug Reimbursement Information and Assistance**
 - **Financial Assistance**
 - **Government Assistance**
 - **Guidance and Support**
 - **Housing and Travel Assistance**
 - **International Support**
 - **Legal Assistance**
 - **Pain Management**
 - **Transplant Resources**
 - **Other Cancer Resources**
 - Veterans Against Myeloma
 - <https://www.myeloma.org/veterans-against-myeloma>
 - M-Power
 - **IMF's Infoline**
 - <https://www.myeloma.org/infoline>
- 800-452 CURE (2873)**
- **Email: infoline@myeloma.org**
 - IMF Medical Research

- Black Swan Research Initiative
- International Myeloma Working Group
- Asian Myeloma Network
- Road to the Cure
- Nurse Leadership Board
 - Nurse Leadership Board Members
 - Nurse Leadership Board Publications
 - Nursing Resources

Multiple Myeloma Research Foundation

<https://themmrf.org/>

- Blogs
 - What You Should Know About the New Zenbexus (iberdomide) Approval
 - How to Make Smarter Decisions at Every Step of Your Myeloma Journey
 - Hearn Jay Cho, MD, PhD on the Evolution and Future of Myeloma Care
 - Horizon One Clinical Trial Beats Enrollment Goals, Plans New Treatment Arm
 - 2026 MMRF NYC Walk to Honor Myeloma Advocate and Patient Terry Glassman (Long Island MM Support Group Leader)
- Navigating Diagnosis & Treatment
- Finding Support
 - Patient Navigation Center

- Myeloma Mentors
- Education Resource Hub
 - Videos
 - New Myeloma Downloadable Fast Fact Cards
 - MMRF Patient Toolkit
 - Events
 - Beyond the Headlines: What New Research at IMS Means for Patients
 - September 30 @ 5:00 pm EDT
 - Patient Summit in Partnership with UCSF Health
 - October 24 @ 11:00 am EDT
 - Patient Summit in Partnership with University of Miami
 - November 5 @4:00pm EDT
- Patient Navigation Center
 - **Monday–Friday, 9 AM–7 PM ET 1-888-841-MMRF (6673)**
 - Information and Resources
 - Perspective on Treatments
 - Support
 - Get on the Right Path for You
 - Right Team
 - Right Tests
 - Right Treatment
 - Meet the Patient Navigators
 - Connect with a Myeloma Mentor

Myeloma Matters – MMRF Podcast

<https://www.youtube.com/playlist?list=PL6YqSpftWXYZht7lBSsLFkyvKsWAZSGq4>

- Great Topics!

HeathTree Foundation for Multiple Myeloma

<https://healthtree.org/>

- HealthTree has reformatted their website. To receive the most benefit, you can create a free account. For the purposes of this recap, here is the information from my feed...
- <https://healthtree.org/myeloma/my-feed>
 - Why Hydration Matters for People with Myeloma
 - Returning to Work After a Stem Cell Transplant

HealthTree University – YouTube

<https://www.youtube.com/c/HealthTreeUniversity>

- Free Light Chains and the Kappa/Lambda Free Light Chain Ratio: Top Things You Should Know
 - <https://www.youtube.com/watch?v=g14i4Dlv1II>
- Chromosomal Mutations Explained: What Are Deletions, Duplications & Translocations
 - https://www.youtube.com/watch?v=dzW-_UlrnCY

SparkCures

<https://sparkcures.com/>

- Myeloma Support...Personalized.
- “Whether it's clinical trials, treatments or finding a myeloma specialist, we help you understand your myeloma options”
- 888-828-2206
- Now featuring trial options for MDS (Myelodysplastic Syndromes) and NTRK Gene Fusion Cancers

Myeloma Central

<https://www.myelomacentral.com/>

- Standing in the Gaap
 - Resources for African Americans
- Multiple Myeloma Resources for Nurses

Cure

<https://www.curetoday.com/tumor/myeloma>

- Latest News
 - Mariska Hargitay Honors Father Through Myeloma Awareness Effort
 - FDA Approves Zenbexus (Iberdomide) Combination for Patients With Multiple Myeloma After Prior Treatment
 - Etentamig Improves Responses and Progression-Free Survival in Relapsed Multiple Myeloma
 - Bristol Myers Squibb Reports Positive Results for CAR T-Cell Therapy in Heavily Pretreated Multiple Myeloma

- Video Series
- Latest Videos
- Shorts
- Podcasts
- More News

Cure – Cancer Horizons

<https://www.curetoday.com/cancer-horizons>

- Choose “Myeloma”
 - Understanding the Use of Bispecific Antibodies in Multiple Myeloma
 - Communication is Key When Transitioning Multiple Myeloma Care
 - What Is CAR-T Cell Therapy, and What Can Patients With Cancer Expect?

OncLive/OncLive Videos

<https://www.onclive.com/clinical/multiple-myeloma>

- Latest News
 - Linvoseltamab Improves Health-Related Quality of Life in Relapsed/Refractory Multiple Myeloma
 - Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma

- <https://www.onclive.com/view/dr-banerjee-on-the-fda-approval-of-iberdomide-plus-daratumumab-dexamethasone-in-r-r-myeloma>
- Video Series
- Latest Videos
- Shorts
- Podcasts
 - FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO
- More News
 - Many great articles

Multiple Myeloma Hub

<https://multiplemyelomahub.com/>

- News
 - How to transition patients to community-based bispecific antibody therapy
 - IMS/IMWG consensus genomic staging for high-risk MM: A cohort study in NDMM
 - Visual abstract | SUCCESSOR-2: A phase III trial of MeziKd for RRMM
 - How to manage toxicities associated with bispecific antibody therapy for MM in community practice
- Recent Content
 - Prognostic value of MRD dynamics in NDMM

- Belantamab mafodotin in RRMM: Latest updates and practical considerations
- Most Read
 - Multiple Myeloma Hub Symposiums
- Steering Committee Meetings
- Drug Updates

Multiple Myeloma Hub Podcast

<https://podcasts.apple.com/us/podcast/multiple-myeloma-hub/id1513939744>

- How to transition patients to community-based bispecific antibody therapy

Patient Power

<https://www.patientpower.info/community/multiple-myeloma>

American Society of Hematology (ASH)

<https://www.hematology.org/>

The ASCO Post

<https://ascopost.com/search-results/?q=myeloma>

- Robert A. Kyle, MD, Myeloma Expert, Dies at 98
- Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses

- FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma
- Technology-Enabled Intervention for HCT Recipients, Primary Care Doctors May Improve Skin Cancer Screening

ASCO Daily News

<https://dailynews.ascopubs.org/action/doSearch?AllField=myeloma>

ASCO Daily News Podcasts

<https://dailynews.ascopubs.org/podcasts>

ASCO Publications

- Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma
 - <https://ascopubs.org/doi/10.1200/EDBK-26-517460>

Blood

<https://ashpublications.org/blood/issue-covers>

- Bispecific CAR T for extramedullary myeloma: a minute waltz
 - <https://ashpublications.org/blood/article/148/7/797/570030/Bispecific-CAR-T-for-extramedullary-myeloma-a>

- GPRC5D CAR-T: a new path beyond BCMA
 - <https://ashpublications.org/blood/article/148/10/1221/570559/GPRC5D-CAR-T-a-new-path-beyond-BCMA>
- NF-κB as a compass for CAR-T fitness in multiple myeloma
 - <https://ashpublications.org/blood/article/148/11/1367/570690/NF-B-as-a-compass-for-CAR-T-fitness-in-multiple>
- Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma
 - <https://ashpublications.org/blood/article/148/10/1240/568830/Arlocabtagene-autoleucel-a-GPRC5D-targeted-CAR-T>

Blood Cancer Talks – Podcast

<https://podcasts.apple.com/us/podcast/blood-cancer-talks/id1633724992>

- Episode 74. Myeloma Updates from ASCO/EHA 2026 with Dr. Prashant Kapoor

The Patient Story

<https://thepatientstory.com/patient-stories/multiple-myeloma/>

Targeted Oncology

<https://www.targetedonc.com/clinical/multiple-myeloma-rc>

Latest News

- Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
 - <https://www.targetedonc.com/view/talquetamab-shows-durable-responses-in-r-r-mm-at-3-year-follow-up>
- Longitudinal Data Shapes Our Understanding of High-Risk Multiple Myeloma
 - <https://www.targetedonc.com/view/longitudinal-data-shapes-our-understanding-of-high-risk-multiple-myeloma>
- Etentamig Improves Response, Survival in Phase 3 Trial for Relapsed/Refractory Myeloma
- Arlo-Cel Meets Efficacy End Point in Quadruple-Class Exposed Myeloma
- Dosing and Toxicity Considerations for Heavily Pretreated Patients With Myeloma
- Risk-Adapted Quadruplet Therapy Sustains 5-Year Survival Benefit in High-Risk Myeloma
- Video Series
- Latest Videos
- Shorts
 - Personalizing Therapy After Iberdomide Approval in Myeloma
- Podcasts
- More News
 - CEPHEUS Data Show Deeper MRD Response With D-VRd in Newly Diagnosed Myeloma

- Immune Profiling Could Optimize T-Cell Therapy in Relapsed Myeloma
- Bridging Before CAR T in Myeloma Should Aim For Deep Response, Not Just Stability

Cancernetwork

<https://www.cancernetwork.com/>

- “Cancer Focus – choose myeloma”
- Latest News
 - Making Nuanced Decisions on CAR-T and Bispecifics in Multiple Myeloma
 - Daratumumab Combo Sets New OS Benchmark in Transplant-Ineligible NDMM
 - How Will Iberdomide’s Approval and Other CELMoDs Impact Multiple Myeloma?
 - Etentamig Improves ORR/PFS in Relapsed/Refractory Multiple Myeloma
- Video Series
- Video Interviews
- Shorts
 - CELMoD Approval Brings “Familiar” Dosing Protocols to Multiple Myeloma
- Podcasts
 - Unpacking Iberdomide’s FDA Approval and The Future of CELMoDs
- More news

- Evolving Treatment Strategies in Relapsed/Refractory Multiple Myeloma

Patient Empowerment Network

<https://powerfulpatients.org/cancer-diagnosis/multiple-myeloma/>

- Is CAR T-Cell Therapy Right for Your Myeloma? Understanding the Process
 - <https://powerfulpatients.org/resource/is-car-t-cell-therapy-right-for-your-myeloma-understanding-the-process/>

Smart Patients

<https://www.smartpatients.com/site>

HemOnc Pulse (Podcast)

<https://www.bloodcancerstoday.com/category/hemonc-pulse>

- Great podcasts on Myeloma

Blood & Marrow Transplant Information Network

<https://bmtinfonet.org/>

- “Blood & Marrow Transplant Information Network (BMT InfoNet) is not-for-profit 501 (c) 3 organization dedicated to providing transplant and CAR T-cell therapy recipients and their loved ones with emotional support and high quality, easy-to-understand information about bone marrow, peripheral blood stem cell and cord blood transplant, and CAR T-cell therapy.”

Blood Cancer United (formerly LLS)

<https://bloodcancerunited.org/>

- Hematology Horizons Vlog Series
<https://bloodcancerunited.org/resources/educational-resources/video/hematology-horizons-vlog-series>
 - Blood Cancer Close to Home
 - Navigating Loss and Grief After A Cancer Diagnosis
 - Advances in CAR t-cell Therapy
- The Bloodline with Blood Cancer United Podcast
<https://thebloodline.org/episodes/>
 - Advocating for Yourself: Insurance, Finances, and Your Rights
 - Making Your Voice Count: The Power of Patient Advocacy
- Blood Cancer United Vodcasts
<https://bloodcancerunited.org/resources/educational-resources/video/bloodline-breakthroughs-innovations-inspiration>

- Blood Cancer United Video and Webcasts
 - <https://bloodcancerunited.org/resources/educational-resources/webcasts-videos>
 - Bispecific antibodies explained for blood cancers

Weekly Online Chat:

- **Veterans Living with Blood Cancer**
 - **Every Tuesday Evening @ 8:00-10:00pm EDT**
- **Online Chat for Caregivers:**
 - **Every Thursday Evening @ 8:00-10:00 pm EDT**
- **Online Chat Living with Myeloma:**
 - **Every Monday Evening @ 8:00-10:00 pm EDT**
- **Online Chat for Patients and Caregivers - Banding Together: Feeling Good Fridays**
 - **Every Friday @ 1:00-3:00 pm EDT**

<https://bloodcancerunited.org/resources/patients/online-chats>

- About Us
 - About Blood Cancer United
 - Featured Programs
 - Partners and Suppliers
 - Stories and News
- Financial Assistance
 - Financial Support
 - Additional Financial Assistance
 - Claims
- Local Groups
 - Find your Region

- Blood Cancers
 - Types of Blood Cancer
- Navigating Your Care
 - Adults
 - Young Adults
 - Children and Teens
- Resources
 - Patient Resources
 - Caregiver Resources
 - Healthcare and Professional Resources
 - Educational Resources
 - Support Resources
 - Blood Cancer Information Specialist
 - 1-800-955-4572
 - Clinical Trial Nurse Navigators
 - Registered Dietitian
 - Newsroom

Oncology Nursing News

https://www.oncnursingnews.com/search?oncnurse_sanity_data%5Bquery%5D=myeloma

- Latest News
- Video Series
- Video Interviews
- Podcasts
- More News

VJHemonc (Video Journal of Oncology)

<https://www.vjhemonc.com/subject/multiple-myeloma/>

- The Multiple Myeloma Channel (Great information)
 - Latest Videos
 - The potential health economic benefits of T-cell redirecting therapy in myeloma
 - Improving access to T-cell redirecting therapies for multiple myeloma: outpatient care models
 - The Myeloma Sessions
 - Conferences
 - Topics
 - Features
 - Etentamig demonstrates significantly improved ORR and PFS in R/R multiple myeloma: CERVINO topline results
 - Podcasts
 - Sequencing therapies in multiple myeloma: navigating an expanding treatment landscape

Triage Cancer

<https://trriagecancer.org/>

- Events
 - **Webinars**
 - **Open Enrollment: Reviewing, Reevaluating, Renewing**

- **September 22 @ 2:00pm EDT**
 - **Understanding Changes to Medicaid & the Marketplace: What Patients and Caregivers Need to Know**
 - **October 1 @ 7:00pm EDT**
 - **Make the Most of Medicare Open Enrollment**
 - **October 13 @ 2:00pm EDT**
- Resources
- Materials
- Support

IMSound (International Myeloma Society Audio Short Series)

<https://www.myelomasociety.org/imsound/>

- “IMSound, the latest audio series from the International Myeloma Society! Each episode brings insights from top experts on crucial issues in the myeloma community”

Oncology Central

<https://www.oncology-central.com/?s=myeloma>

- Major improvements in survival observed for multiple myeloma patients undergoing precision treatment
- Other Interesting Articles

Blood Cancers Today

<https://www.bloodcancerstoday.com/>

- Multiple Myeloma Advances With Bispecific and Trispecific Antibodies (Dr. Richter)
- Systematic Review Consolidates Efficacy of GPRC5D-Directed Therapies for RRMM
- The Role of Plant-Based Diets in MGUS and Smoldering Myeloma (Dr. Urvi Shah)
- Impact of Disease Biology in Patients with Relapsed/Refractory Multiple Myeloma Following CAR-T Cell Therapy
- Iberdomide FDA Approval Marks ‘A Big Step Forward’ for Patients With RRMM (Dr. Sagar Lonial)
- Advancing Real-World Data in Multiple Myeloma: Closing the Gap Between Trials and the Clinic
- Plus many good articles!

Hemonc Pulse – Podcast

<https://www.bloodcancerstoday.com/category/hemonc-pulse>

X

- Dr. Henry Fung – He posts the bests MM diagrams on twitter!!
 - ClonoSEQ

- <https://x.com/HenrychihangFu1/status/2089122973017903599?s=58&t=7w0ni0WXD12zMKqXp8TQjQ>
- Dara-Iber-Dex: FDA approved. But where does it fit?
 - <https://x.com/HenrychihangFu1/status/2089677383007662410?s=58&t=7w0ni0WXD12zMKqXp8TQjQ>
- High-risk smoldering multiple myeloma: Dara vs Carvykti vs teclistamab
 - <https://x.com/HenrychihangFu1/status/2099108435011027013?s=58&t=7w0ni0WXD12zMKqXp8TQjQ>
- MyCancerHaven
 - in-Vivo CAR-T Cells: The Wave of the Future in Myeloma Care | Binod Dhakal, MD (video)
 - <https://www.youtube.com/watch?v=vJPMHqFuoTg>
- Healthcare Unfiltered Podcast
 - <https://podcasts.apple.com/us/podcast/healthcare-unfiltered/id1534737585>
 - Episode 292 - CELMoDs in Myeloma: A Report From EHA with Drs. Sagar Lonial and Vincent Rajkumar
- OncUpdates

- 2 Years of Maintenance May Be Enough for Some Patients With Standard-Risk Multiple Myeloma: ENDURANCE Trial Breakdown
 - <https://oncupdates.com/article/2-years-of-maintenance-may-be-enough-for-some-patients-with-standard-risk-multiple-myeloma-endurance-trial-breakdown/>
- Wiley Online Library
 - Older and frail patients with multiple myeloma treated with bispecific antibodies: A systematic review and meta-analysis
 - <https://onlinelibrary.wiley.com/doi/10.1111/bjh.70804>
 - Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers
 - <https://onlinelibrary.wiley.com/doi/10.1111/bjh.70612>
- American Journal of Managed Care
 - Inside Myeloma's Evolution From Death Sentence to Cure
 - <https://www.ajmc.com/view/inside-myeloma-s-evolution-from-death-sentence-to-cure>

The Fellow on Call Podcast

<https://www.thefellowoncall.com/>

Dr. Rafael Foncesca's Substack

<https://rafaelfonseca.substack.com/>

- How I treat relapsing myeloma (MM) with CART (cilta-cel)
 - https://rafaelfonseca.substack.com/p/how-i-treat-relapsing-myeloma-mm?r=92kzs&utm_campaign=post&utm_medium=web
- Great articles and diagrams!

OncoDaily

<https://oncodaily.com/hematology>

- Arlocabtagene Autoleucel (Arlo-cell) Meets Primary Endpoint in Phase 2 QUINTESSENTIAL Trial for Multiple Myeloma
- The Second Act of Thalidomide: How a Withdrawn Drug Gave Rise to a New Class of Myeloma Therapy
- Etentamig Improves Response Rate and PFS in Phase 3 CERVINO Multiple Myeloma Trial

Bristol Meyers Squibb

- **U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj**

and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

- <https://news.bms.com/news/corporate-financial/2026/U-S--FDA-Grants-Accelerated-Approval-to-Bristol-Myers-Squibbs-First-CELMoD-Therapy-ZENBEXUS-in-Combination-with-Daratumumab-and-Hyaluronidase-fihj-and-Dexamethasone-ZDd-for-Patients-with-Multiple-Myeloma-as-Early-as-First-Relapse/default.aspx>

AbbVie

- **AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma**
 - <https://news.abbvie.com/2026-09-03-AbbVie-Announces-Positive-Topline-Results-from-the-Phase-3-CERVINO-Trial-Showing-Etentamig-Significantly-Improved-Response-Rate-and-Progression-Free-Survival-in-Patients-with-Relapsed-Refractory-Multiple-Myeloma>

National Library of Medicine

- **“Standing on the Shoulders of Giants” Dr. Robert Kyle and Dr. Mohamad Mohty**

- <https://pmc.ncbi.nlm.nih.gov/articles/PMC10063761/>
 - Dr. Mohty interviews Dr. Kyle
- Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma
 - <https://pubmed.ncbi.nlm.nih.gov/42687830/>